secwatch.observer — SEC 8-K summary
======================================

Issuer:     Onconetix, Inc. (ONCO)
CIK:        0001782107
Form:       8-K
Filed at:   2024-01-12T23:59:59+00:00
Accession:  0001213900-24-003413
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Onconetix CEO Neil Campbell resigns; interim CEO and Lead Independent Director appointed
--------------------------------------------------------------------------------

- Dr. Neil Campbell resigned as President, CEO, and board member effective Jan 10, 2024; no disagreement cited.
- Campbell receives $158,333 severance payment under a release of claims filed as Exhibit 99.1.
- Dr. Ralph Schiess, Chief Science Officer, appointed Interim CEO effective Jan 12, 2024.
- James Sapirstein named Lead Independent Director; will receive $40,000 per month for that role.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782107/000121390024003413/0001213900-24-003413-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782107/000121390024003413/ea191591-8k_onconetix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-003413

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer